IIIuliana Iordan

Iuliana Iordan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iuliana Iordan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cutaneous Complications after Autologous Stem Cell Transplantation

    by Ana-Maria Ilinescu, Ana-Maria Vladareanu, Elena Georgiana Ene, Iuliana Iordan, Horia Bumbea

    Autologous stem cell transplantation (ASCT) has become more prevalent for high-grade non-Hodgkin's lymphoma (NHL) over the past decade. ASCT serves as a salvage treatment for high-risk or relapsed patients, offering potential long-term remission. Cutaneous modifications post-ASCT can be classified as early (within 100 days) and late (after 100 days). Understanding these changes is crucial for timely diagnosis and management. Early modifications typically include transient erythema, hyperpigmentation, and acute dermatitis, often linked to the conditioning regimen. Late modifications, occurring months to years posttransplantation, can encompass chronic skin changes such as scleroderma-like features and persistent pigmentary alterations. Emerging evidence challenges the notion that ASCT is free of graft-versus-host disease (GVHD), with incidences of auto-GVHD reported. However, cutaneous GVHD post-ASCT, though uncommon, poses significant diagnostic challenges. Cutaneous GVHD manifestations range from mild eruptions to severe, systemic involvement. The role of skin biopsy in these cases is invaluable, providing histopathological confirmation and distinguishing GVHD from other dermatoses. Recognizing the early and late cutaneous modifications following ASCT is essential for clinicians. Despite the rarity of skin GVHD in ASCT, awareness and prompt biopsy can facilitate accurate diagnosis and appropriate management, improving patient outcomes.

  • Open Access

    Frequency of thrombophilia-associated mutations and polymorphisms in pregnant women with a history of thrombosis or pregnancy complications

    by Ana-Maria Vlădăreanu, Minodora Onisâi, Iuliana Iordan, Eugen Radu, Adrian Roşca, Octavian Munteanu, Dan Sebastian Soare, Cristina Mambet, Suzana Elena Voiculescu, Horia Bumbea, et al.

    Objectives: To assess the frequency of multiple thrombophilia-associated mutations and polymorphisms in a selected population of high-risk pregnancies. Methods: Thrombophilia screening was performed for 1,500 pregnant women with prior pregnancy complications or thrombotic events. Nine thrombophilia-associated mutations or polymorphisms were screened: factor V Leiden, factor V H1299R, prothrombin G20210A, MTHFR C677T, MTHFR A1298C, factor XIII V34L, PAI-1 4G/5G polymorphisms, EPCR G4600A, EPCR C4678G. Results: Out of the 1,500 patients, 1,291 fulfilled the criteria for data interpretation. All patients had low-risk thrombophilia-associated genetic variants. Only 1.24 % of cases presented high-risk abnormalities (homozygous factor V Leiden/prothrombin G20210A, or both mutations in heterozygous form). Heterozygous factor V Leiden occurred in 10.38 % of cases, while only 5.81 % carried heterozygous prothrombin G20210A mutation. The frequency of prothrombin G20210A mutation was higher (10.37 %) in the subgroup associating factor V Leiden, than in the subgroup lacking it (5.36 %). Low-risk genetic variants occurred with a higher frequency: 23.78 % factor V H1299R, 57.32 % MTHFR C677T, 55.54 % MTHFR A1298C, 44.07 % factor XIII V34L, 73.20 % PAI-1 4G/5G polymorphisms, 69.64 % EPCR G4600A, and 69.63 % EPCR C4678G. Conclusions: All patients had at least one prothrombotic genetic mutation or variant. Our data highlight the need for thrombophilia screening, including low-risk genetic variants, in a high-risk population of pregnant women with a history of pregnancy complications or thrombotic events.


  • Open Access

    Complicaţii mediate imunologic ale anticorpilor monoclonali folosiţi în oncohematologie

    by Iuliana Iordan, Dan-Corneliu Jinga, Claudiu Dragoş Popescu, Ana Maria Vlădăreanu

    Monoclonal antibodies have emerged as effective treat­ments for a wide range of hematological and oncological dis­or­ders. Even though the majority of these medications have a superior tolerance and safety profile than traditional che­mo­the­ra­py, an increasing number and variety of im­mune-mediated complications have been identified. There have been reports of both hematological and non-he­ma­to­lo­gical side effects which can affect almost every organ. There­fore, clinicians must be aware of these adverse events since the early detection and the correct therapy are critical in reducing morbidity and mortality.

  • Open Access

    Trombocitopenia imună refractară – prezentare de caz

    by Iuliana Iordan, Andreea Neculcea, Stejara Nicoleta Mihai, Diana Emanuela Bonea, Andreea Spînu, Alina Mititelu, Claudiu Popescu, Raluca Truican, Anca Nicolescu, Ana Maria Prof. Dr. Vlădăreanu

    Immune thrombocytopenia is an autoimmune disorder that involves the platelet destruction in the spleen. Often, pa­tients do not respond to conventional therapy. The ma­nage­ment of refractory or relapsed immune throm­bo­cy­to­penia poses a challenge for hematologist. We report the case of a 43-year-old patient in whom conventional treat­ment was not successful but who responded to TPO agonist el­trom­bopag.

  • Open Access

    Un caz rar de limfom Burkitt agresiv cu multiple infiltrate extranodale la un vârstnic

    by Iuliana Iordan, Andreea Neculcea, Diana Emanuela Bonea, Dragoş-Claudiu Popescu, Alina Mititelu, Andreea Spînu, Paul Findrihan, Raluca Nistor, Ana Maria Vlădăreanu

    Burkitt lymphoma is one of the most aggressive non-Hodgkin lymphomas. The disease can be associated with extranodal involvement, especially in the structures of the neck and head, abdomen, kidneys and bone marrow. Breast involvement is rare. This type of lymphoma has an intrinsic propensity for central nervous system involvement. We report the case of an elderly patient diagnosed with Burkitt lymphoma with breast tumor and central nervous system infiltrates.